Reversal of preexisting neuropathic pain by spinal delivery of AIBP
通过脊髓输送 AIBP 逆转先前存在的神经性疼痛
基本信息
- 批准号:10197482
- 负责人:
- 金额:$ 37.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAmericanAnimal ModelAnimalsAnticonvulsantsAntiinflammatory EffectApolipoprotein A-IAstrocytesBehavioral AssayBinding ProteinsBiologicalBiological AssayBiological Response Modifier TherapyBiological SciencesBlood - brain barrier anatomyBlood specimenBortezomibBurning PainCaliforniaCell membraneCellular MembraneChemicalsChemotherapy-induced peripheral neuropathyCholesterolChronicCisplatinClinicalCollaborationsDependenceDevelopmentDiabetes MellitusDimerizationDoseDrug KineticsEsthesiaExcisionFormulationFutureGoalsHarvestHyperalgesiaInflammationInflammatoryInjectionsInjuryLaboratoriesLeadLigationMeasurementMediatingMedicalMembrane MicrodomainsMicrogliaMononeuropathiesMusNational Institute of Neurological Disorders and StrokeNerveNeurogliaNeuropathyNon-Steroidal Anti-Inflammatory AgentsOncologyOpioidPainPeripheral NervesPeripheral nerve injuryPersistent painPharmacodynamicsPhasePhenotypePolyneuropathyPreventionProductionProtein ChemistryProteinsProtocols documentationQuality of lifeRegulationResearchResearch DesignResolutionRouteSensorySpinalSpinal CordSpine painStimulusSymptomsTLR4 geneTactileTestingTherapeuticTherapeutic EquivalencyTissuesTranslatingTraumaUniversitiesVirus DiseasesWorkaddictionallodyniabasebrain tissuechemotherapeutic agentchemotherapychronic painclinical developmentconditioned place preferencecytokinedesignepigenglial activationhuman modelimmune activationin vitro Assaymanufacturing processmanufacturing scale-upmouse modelnerve injuryneuroinflammationnovelnovel strategiespain reliefpainful neuropathypharmacokinetics and pharmacodynamicspreclinical developmentprogramsreceptor functionresearch clinical testingresponseside effect
项目摘要
Project Summary
Peripheral nerve injury can lead to anomalous sensations referred to as neuropathic pain. Nerve injury may
result from a variety of insults ranging from frank injury to the nerve though sectioning or compression, and is
particularly prevalent following chemotherapies used in oncology. Symptoms often include continuous burning
pain and abnormal sensory sensations such as allodynia (pain as a result of non-noxious stimuli) and
hyperalgesia (an increased response to a normally painful stimulus) Persistent pain after resolution of clinically
appreciable signs of injury poses a therapeutic challenge and current therapies do not meet this medical need.
Accordingly, novel treatment options that afford additional benefit in prevention or relief of pain are needed. In
this proposal, a collaboration initiated between the University of California San Diego (UCSD) and Epigen
Biosciences Inc. seeks to fully evaluate the apoA-I binding protein (AIBP), an agent that interferes with inflamed
lipid rafts in spinal glia and has been found to reverse facilitated pain states in several mouse models. The goals
of this proposal during the R21 phase include the AIBP protein manufacture and characterization,
pharmacokinetics studies, design and refinement of experimental animal protocols to assess efficacy and
pharmacodynamics of AIBP in mouse models of polyneuropathy (induced by chemotherapeutic agents) and
mononeuropathy (L5 nerve ligation), and optimization of pharmacodynamics assays to evaluate AIBP
engagement of spinal glia and its anti-inflammatory effects. Contingent upon the successful completion of a set
of proposed milestones, the R33 phase will commence to establish dose-dependent efficacy profile for AIBP
treatment of neuropathic pain and to correlate it with AIBP pharmacokinetics and pharmacodynamics. The
proposal is designed to advance the AIBP project to the point where it can meet the entry criteria for NINDS
Cooperative Research to Enable and Advance Translational Enterprises (CREATE) program, with the ultimate
goal to develop a novel biologic therapeutics for management of persistent pain states.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yury Miller其他文献
Yury Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yury Miller', 18)}}的其他基金
Reversal of preexisting neuropathic pain by spinal delivery of AIBP
通过脊髓输送 AIBP 逆转先前存在的神经性疼痛
- 批准号:
9750836 - 财政年份:2018
- 资助金额:
$ 37.67万 - 项目类别:
Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis
动脉粥样硬化中炎症巨噬细胞的胆固醇调节
- 批准号:
10188606 - 财政年份:2017
- 资助金额:
$ 37.67万 - 项目类别:
Project 2: Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis
项目2:动脉粥样硬化中炎症巨噬细胞的胆固醇调节
- 批准号:
10334095 - 财政年份:2017
- 资助金额:
$ 37.67万 - 项目类别:
Early Forms of Oxidized LDL, TLRs and Atherosclerosis
氧化 LDL、TLR 和动脉粥样硬化的早期形式
- 批准号:
7839765 - 财政年份:2009
- 资助金额:
$ 37.67万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 37.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 37.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 37.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)